Abstracts tagged "Animal models"

Abstract Number: 400 • 2017 ACR/ARHP Annual Meeting
Combination of the Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation Models As a Model of Interstitial Lung Disease in Rheumatoid Arthritis
Katherine Janike¹, Jill Poole¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell W. Klassen⁴, Amy Nelson⁵, Kristi Warren⁶, Benjamin Swanson⁷ and Ted R. Mikuls⁸, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Int Med/Sec of Rheum/Immun, Univ of NE Medical Ctr, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, University of Nebrasa Medical Center, Omaha, NE, ⁶Department of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including interstitial/inflammatory lung disease (ILD). Whereas the coexistence of RA and ILD is known, mechanisms…
Abstract Number: 1327 • 2017 ACR/ARHP Annual Meeting
Decreased Inflammatory Arthritis in Human Serum Paraoxonase 1 Transgenic Mice
Christina Charles-Schoeman¹, Ani Shahbazian², Jennifer Wang³, Victor Grijalva⁴ and Srinivasa T. Reddy⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Medicine-Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid…
Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Ji Yong Choi¹, Joo Youn Lee², Ji Soo Park³, Sehui Shon³, Kathleen Phillips⁴, Eun Young Lee¹, Eun Bong Lee¹ and Yeong Wook Song^3,5, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Pfizer Inc. Cambridge, MA. USA, Cambridge, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…
Abstract Number: 401 • 2017 ACR/ARHP Annual Meeting
Cigarette Smoking Dose-Dependently Facilitates the Onset of Arthritis and Aggravates Arthritis in Female Experimental Arthritis Mice
Ji-Won Kim¹, Jennifer Lee², Yeon-Sik Hong³, Sung-Hwan Park² and Ji Hyeon Ju², ¹Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Smoking is an important epidemiological factor for development of rheumatoid arthritis (RA). However, the mechanism of proarthritic role of smoking is not well understood.…
Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Stacey Dillon¹, Katherine Lewis¹, Ryan Swanson², Lawrence Evans², Michael Kornacker³, Steve Levin², Martin Wolfson⁴, Erika Rickel², Susan Bort², Sherri Mudri¹, Aaron Moss¹, Michelle Seaberg¹, Janhavi Bhandari⁴, Sean MacNeil⁴, Joe Hoover⁴, Mark Rixon⁴ and Stanford Peng⁵, ¹Translational Sciences, Alpine Immune Sciences, Seattle, WA, ²Immunology, Alpine Immune Sciences, Seattle, WA, ³Protein Engineering, Alpine Immune Sciences, Seattle, WA, ⁴Protein Therapeutics, Alpine Immune Sciences, Seattle, WA, ⁵Clinical, R&D, Alpine Immune Sciences, Seattle, WA
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…
Abstract Number: 2227 • 2017 ACR/ARHP Annual Meeting
S100A9 Induces a Pain Response during Experimentally Induced Acute Synovitis
Arjen B. Blom¹, Edwin J. W. Geven¹, Martijn H. van den Bosch¹, Esmeralda N. Blaney Davidson¹, Peter M. van der Kraan¹ and Peter L. van Lent², ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Center, Rheumatology, Nijmegen, Netherlands
Background/Purpose: Synovitis-associated pain is an important aspect of arthritis pathology. Several inflammatory mediators released by the synovium have been implicated in the regulation of pain,…
Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting
BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
Kathleen Gillooly¹, Yifan Zhang¹, Xiaoxia Yang¹, Adriana Zupa-Fernandez¹, Lihong Cheng¹, Joann Strnad¹, Mark Cunningham², Elizabeth Heimrich¹, Xiadi Zhou¹, Jing Chen³, Charu Chaudhry³, Sha Li³, Kim McIntyre¹, Julie Carman⁴, Ryan Moslin⁵, Stephen Wrobleski⁵, David Weinstein⁵ and James Burke¹, ¹Immunosciences Discovery Biology, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³Leads Discovery & Optimization, Bristol-Myers Squibb, Princeton, NJ, ⁴Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ⁵Immunosciences Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ

Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…
Abstract Number: 1031 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Receptor Dimerization in Stromal Cells Modulates Macrophage Polarization during Serum Transfer-Induced Arthritis
Mascha Koenen¹, Ulrike Baschant^2,3, Stephan Culemann^3,4, Tobias Kockmann⁵, Hans-Michael Kaltenbach⁶, Sabine Vettorazzi^1,3, Paolo Nanni⁷, Bernd Roschitzki⁸, Ulrich Auf dem Keller⁹ and Jan P. Tuckermann^1,3, ¹Institute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany, ²Dep. of Medicine III, TU Dresden, Dresden, Germany, ³Leibniz Institute on Aging, FLI Jena, Jena, Germany, ⁴Dep. of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Institute for Molecular Health Sciences, ETH Zürich, Zürich, Switzerland, ⁶Dep. of Biosystems Science and Engineering, ETH Zürich, Zürich, Germany, ⁷Functional Genomics Center Zurich, University and ETH Zurich, Zürich, Switzerland, ⁸Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ⁹Institute for Molecular Health Sciences, ETH Zürich, Zürich, Germany
Background/Purpose: Rheumatoid arthritis is commonly treated with potent anti-inflammatory glucocorticoids (GC), despite severe side effects such as osteoporosis and insulin resistance associated with chronic dosing…
Abstract Number: 1454 • 2016 ACR/ARHP Annual Meeting
Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis
Julie Di Paolo¹, David Alonzo², Christian Franci³, Terry Gentzler¹, Li Li⁴, Bernard Murray⁵ and Jim Zheng⁵, ¹Biology, Gilead Sciences, Foster City, CA, ²FPD, Gilead Sciences, Foster City, CA, ³Biology, Gilead Sciences, Foster, CA, ⁴Gilead Sciences, South San Francisco, CA, ⁵DMPK, Gilead Sciences, Foster City, CA
Background/Purpose: Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA);…
Abstract Number: 3146 • 2016 ACR/ARHP Annual Meeting
Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation
Adam Paul Croft, Joana Campos, Andrew Filer, Francesca Barone and Chris Buckley, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Despite their role as key effector cells driving synovial inflammation and joint damage, fibroblast like synoviocytes (FLS) have yet to be targeted therapeutically. Fibroblast…
Abstract Number: 1032 • 2016 ACR/ARHP Annual Meeting
Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Katarzyna Matyja^1,2, Matthieu Ribon^1,2, Roxane Hervé^1,2, Delphine Lemeiter^1,2, Ken Tsumiyama³, Natacha Bessis^1,2, Shunichi Shiozawa³, Marie-Christophe Boissier^1,2,4 and Patrice Decker^1,2, ¹Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²UMR 1125, Inserm, Bobigny, France, ³Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 3173 • 2016 ACR/ARHP Annual Meeting
Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension
Jerome Avouac¹, Irena Konstantinova², Christophe Guignabert³, Sonia Pezet⁴, Anne Cauvet⁵, Jeremy Sadoine⁶, Thomas Guilbert⁴, Jean-Michel Luccarini⁷, Jean-Louis Junien⁷, Pierre Broqua⁷ and Yannick Allanore⁸, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Inventiva, Daix, France, ³Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ⁴Institut Cochin, INSERM U1016, Paris, France, ⁵INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Equipe d’Accueil (EA) 2496 Pathologie, Imagerie et Biothérapies Orofaciales, Faculty of Odontology, Paris Descartes University, Montrouge, France, ⁷Inventiva, DAIX, France, ⁸Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors known to modulate fibrosis. The pan-PPAR agonist IVA337 recently demonstrated efficacy in prevention and treatment of experimental…
Abstract Number: 1034 • 2016 ACR/ARHP Annual Meeting
Microrna-146a Controls Local Bone Destruction By Regulating Fibroblast Induced Osteoclastogenesis in Inflammatory Arthritis
Victoria Saferding¹, Antonia Puchner², Eliana Goncalves-Alves³, Melanie Hofmann³, Julia Brunner⁴, Emine Sahin⁴, Silvia Hayer⁵, Philippe Georgel⁶, Marije M. Koenders⁷, Gernot Schabbauer⁴, Josef S. Smolen⁸, Günter Steiner⁹, Kurt Redlich³ and Stephan Blüml¹⁰, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Vascular Biology and Thrombosis research, Medical University of Vienna, Vienna, Austria, ⁵Waehringer Guertel 18-20 A-A09, Medical University of Vienna, Vienna, Austria, ⁶Centre de Recherche en Immunologie et Hématologie, Université de Strasbourg, Strasbourg, France, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁸Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁰Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: MicroRNA (MiR-) 146a plays an important role in the regulation of the innate immune response and has also been shown to suppress cancer development…
Abstract Number: 1458 • 2016 ACR/ARHP Annual Meeting
Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?
Hubert Stangl, Christine Wolff, Martin Lesiak and Rainer Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: In rheumatoid arthritis (RA) and collagen-induced arthritis (CIA) the phenomenon of a relative insufficiency of adrenal glands to produce an adequate amount of anti-inflammatory…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].